Picture EBD Group World of Partnering Opportunities 650x100px
Document › Details

PolyPeptide Group AG. (10/2/23). "Press Release: PolyPeptide Secures Revolving Credit Facility". Baar.

Organisations Organisation PolyPeptide Group AG (SIX: PPGN)
  Group PolyPeptide (Group)
  Organisation 2 Credit Suisse (Group)
  Today UBS (Group)
  Group UBS (Group)
Product Product  finance
Person Person Stäheli, Michael (PolyPeptide 202305 Head of IR + Corp Communications)

PolyPeptide Group AG (SIX: PPGN) announces the signing of a revolving credit facility agreement with Credit Suisse, Danske Bank and Zürcher Kantonalbank as mandated lead arrangers, complemented by the extension of the credit facility with its majority shareholder, concluding the previously disclosed financing negotiations.

With Credit Suisse as the coordinator and agent, the banks committed to a three-year revolving credit facility (RCF) in the amount of EUR 111 million with an uncommitted increase option of EUR 40 million. The RCF allows PolyPeptide to refinance its existing borrowings from banks as well as finance its working capital and capital expenditure requirements to support its planned business growth.

In parallel, Draupnir Holding B.V. agreed to extend its EUR 40 million credit facility, which may be refinanced under the RCF subject to certain conditions.

Lalit Ahluwalia, CFO of PolyPeptide, comments: «The financing gives us the flexibility to invest to meet the needs of our customers as we implement our turnaround plans. We remain focused on operational execution while managing costs and optimizing net working capital.»


Michael Stäheli
Head of Investor Relations & Corporate Communications
T: +41 43 502 0580

About PolyPeptide

PolyPeptide Group AG with its consolidated subsidiaries (“PolyPeptide”) is a focused Contract Development & Manufacturing Organization (CDMO) for peptide- and oligonucleotide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide offers products and services from pre-clinical through to commercial stages, including generics. Its active custom projects pipeline reflects the opportunities from novel drug therapies in development to fight both widespread and rare diseases. Dating back to 1952, PolyPeptide today runs a global network of six cGMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. For more information, please visit

@PolyPeptide – follow us on LinkedIn


This media release has been prepared by PolyPeptide Group AG and contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual developments to differ materially from those expressed or implied in this release. PolyPeptide Group AG is providing the information in this release as of this date and, except as required by applicable laws or regulations, does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.

Record changed: 2024-01-06


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for PolyPeptide (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group World of Partnering Opportunities 650x300px

» top